

[FDA Home](#)³ [Drug Databases](#)⁴ [Orange Book](#)⁵

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Search results from the "OB_Rx" table for query on "200533."

Active Ingredient: TAPENTADOL HYDROCHLORIDE
Dosage Form;Route: TABLET, EXTENDED RELEASE;ORAL
Proprietary Name: NUCYNTA ER
Applicant: JANSSEN PHARMS
Strength: EQ 50MG BASE
Application Number: N200533
Product Number: 001
Approval Date: Aug 25, 2011
Reference Listed Drug: No
RX/OTC/DISCN: RX
TE Code:

Patent and Exclusivity Info for this product: [View](#)

Active Ingredient: TAPENTADOL HYDROCHLORIDE
Dosage Form;Route: TABLET, EXTENDED RELEASE;ORAL
Proprietary Name: NUCYNTA ER
Applicant: JANSSEN PHARMS
Strength: EQ 100MG BASE
Application Number: N200533
Product Number: 002
Approval Date: Aug 25, 2011
Reference Listed Drug: No
RX/OTC/DISCN: RX
TE Code:

Patent and Exclusivity Info for this product: [View](#)

Active Ingredient: TAPENTADOL HYDROCHLORIDE
Dosage Form;Route: TABLET, EXTENDED RELEASE;ORAL
Proprietary Name: NUCYNTA ER
Applicant: JANSSEN PHARMS
Strength: EQ 150MG BASE
Application Number: N200533
Product Number: 003
Approval Date: Aug 25, 2011
Reference Listed Drug: No
RX/OTC/DISCN: RX
TE Code:

Patent and Exclusivity Info for this product: [View](#)

Active Ingredient: TAPENTADOL HYDROCHLORIDE
Dosage Form;Route: TABLET, EXTENDED RELEASE;ORAL
Proprietary Name: NUCYNTA ER
Applicant: JANSSEN PHARMS
Strength: EQ 200MG BASE
Application Number: N200533
Product Number: 004
Approval Date: Aug 25, 2011
Reference Listed Drug: No

Purdue Exhibit 1095
Purdue Pharma L.P. v. Depomed, Inc.
Case IPR2014-00377, -00378, -00379

RX/OTC/DISCN: RX
TE Code:
Patent and Exclusivity Info for this product: [View](#)
Active Ingredient: TAPENTADOL HYDROCHLORIDE
Dosage Form;Route: TABLET, EXTENDED RELEASE;ORAL
Proprietary Name: NUCYNTA ER
Applicant: JANSSEN PHARMS
Strength: EQ 250MG BASE
Application Number: N200533
Product Number: 005
Approval Date: Aug 25, 2011
Reference Listed Drug: Yes
RX/OTC/DISCN: RX
TE Code:
Patent and Exclusivity Info for this product: [View](#)

[Return to Electronic Orange Book Home Page](#)⁶

FDA/Center for Drug Evaluation and Research
Office of Generic Drugs
Division of Labeling and Program Support
Update Frequency:

Orange Book Data - **Monthly**

Generic Drug Product Information & Patent Information - **Daily**

Orange Book Data Updated Through November 2014

Patent and Generic Drug Product Data Last Updated December 17, 2014

Links on this page:

1. <http://www.addthis.com/bookmark.php?u508=true&v=152&username=fdamain>
2. <http://www.addthis.com/bookmark.php>
3. <http://www.fda.gov/default.htm>
4. <http://www.fda.gov/Drugs/InformationOnDrugs/default.htm>
5. [../default.cfm](http://www.fda.gov/oc/default.cfm)
6. [../default.cfm](http://www.fda.gov/oc/default.cfm)

Note: If you need help accessing information in different file formats, see [Instructions for Downloading Viewers and Players](#).

[Accessibility](#) [Contact](#) [FDA Careers](#) [FDA Basics](#) [FOIA](#) [No Fear Act](#) [Site Map](#) [Transparency](#) [Website Policies](#)

U.S. Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
Ph. 1-888-INFO-FDA (1-888-463-6332)
[Email FDA](#)



[For Government](#) [For Press](#)

[Combination Products](#) [Advisory Committees](#) [Science & Research](#) [Regulatory Information](#) [Safety](#)
[Emergency Preparedness](#) [International Programs](#) [News & Events](#) [Training and Continuing Education](#)
[Inspections/Compliance](#) [State & Local Officials](#) [Consumers](#) [Industry](#) [Health Professionals](#) [FDA Archive](#)

 U.S. Department of **Health & Human Services**

Links on this page:

1. <http://www.addthis.com/bookmark.php?u508=true&v=152&username=fdamain>
2. <http://www.addthis.com/bookmark.php>
3. <http://www.fda.gov/default.htm>
4. <http://www.fda.gov/Drugs/InformationOnDrugs/default.htm>
5. [../default.cfm](http://www.fda.gov/default.cfm)
6. [../default.cfm](http://www.fda.gov/default.cfm)

[FDA Home](#)³ [Drug Databases](#)⁴ [Orange Book](#)⁵

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Patent and Exclusivity Search Results from query on Appl No 200533 Product 001 in the OB_Rx list.

Patent Data

Appl No	Prod No	Patent No	Patent Expiration	Drug Substance Claim	Drug Product Claim	Patent Use Code	Delist Requested
N200533	001	6071970	Jun 6, 2017			U - 1178	
N200533	001	6071970	Jun 6, 2017			U - 1276	
N200533	001	7994364	Jun 27, 2025	Y	Y	U - 1178	
N200533	001	7994364	Jun 27, 2025	Y	Y	U - 1276	
N200533	001	8075872	Nov 20, 2023		Y		
N200533	001	8114383	Oct 10, 2024		Y		Y
N200533	001	8309060	Nov 20, 2023		Y	U - 1178	
N200533	001	8309060	Nov 20, 2023		Y	U - 1276	
N200533	001	8420056	Nov 20, 2023		Y		
N200533	001	8536130	Sep 22, 2028			U - 1276	
N200533	001	RE39593	Aug 5, 2022	Y	Y	U - 1178	
N200533	001	RE39593	Aug 5, 2022	Y	Y	U - 1276	

Exclusivity Data

Appl No	Prod No	Exclusivity Code	Exclusivity Expiration
N200533	001	I - 656	Aug 28, 2015
N200533	001	NCE	Nov 20, 2013
N200533	001	NDF	Aug 25, 2014

Additional information:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. These patents may not be flagged with respect to other claims which may apply.

[View a list of all patent use codes](#)

[View a list of all exclusivity codes](#)

[Return to Electronic Orange Book Home Page](#)⁶

FDA/Center for Drug Evaluation and Research

Office of Generic Drugs

Division of Labeling and Program Support

Update Frequency:

Orange Book Data - **Monthly**

Generic Drug Product Information & Patent Information - **Daily**

Orange Book Data Updated Through November 2014

Patent and Generic Drug Product Data Last Updated December 12, 2014

Links on this page:

1. <http://www.addthis.com/bookmark.php?u508=true&v=152&username=fdomain>
2. <http://www.addthis.com/bookmark.php>
3. <http://www.fda.gov/default.htm>
4. <http://www.fda.gov/Drugs/InformationOnDrugs/default.htm>
5. [../default.cfm](#)
6. [../default.cfm](#)

Note: If you need help accessing information in different file formats, see [Instructions for Downloading Viewers and Players](#).

[Accessibility](#) [Contact](#) [FDA Careers](#) [FDA Basics](#) [FOIA No Fear Act](#) [Site Map](#) [Transparency](#) [Website Policies](#)

U.S. Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
Ph. 1-888-INFO-FDA (1-888-463-6332)
[Email FDA](#)



[For Government](#) [For Press](#)

[Combination Products](#) [Advisory Committees](#) [Science & Research](#) [Regulatory Information](#) [Safety Emergency](#) [Preparedness](#) [International Programs](#) [News & Events](#) [Training and Continuing Education](#) [Inspections/Compliance](#) [State & Local Officials](#) [Consumers](#) [Industry](#) [Health Professionals](#) [FDA Archive](#)



U.S. Department of **Health & Human Services**

Links on this page:

1. <http://www.addthis.com/bookmark.php?u508=true&v=152&username=fdamain>
2. <http://www.addthis.com/bookmark.php>
3. <http://www.fda.gov/default.htm>
4. <http://www.fda.gov/Drugs/InformationOnDrugs/default.htm>
5. [../default.cfm](#)
6. [../default.cfm](#)



[FDA Home](#)³ [Drug Databases](#)⁴ [Orange Book](#)⁵

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Patent and Exclusivity Search Results from query on Appl No 200533 Product 002 in the OB_Rx list.

Patent Data

Appl No	Prod No	Patent No	Patent Expiration	Drug Substance Claim	Drug Product Claim	Patent Use Code	Delist Requested
N200533	002	6071970	Jun 6, 2017			U - 1178	
N200533	002	6071970	Jun 6, 2017			U - 1276	
N200533	002	7994364	Jun 27, 2025	Y	Y	U - 1178	
N200533	002	7994364	Jun 27, 2025	Y	Y	U - 1276	
N200533	002	8075872	Nov 20, 2023		Y		
N200533	002	8114383	Oct 10, 2024		Y		Y
N200533	002	8309060	Nov 20, 2023		Y	U - 1178	
N200533	002	8309060	Nov 20, 2023		Y	U - 1276	
N200533	002	8420056	Nov 20, 2023		Y		
N200533	002	8536130	Sep 22, 2028			U - 1276	
N200533	002	RE39593	Aug 5, 2022	Y	Y	U - 1178	
N200533	002	RE39593	Aug 5, 2022	Y	Y	U - 1276	

Exclusivity Data

Appl No	Prod No	Exclusivity Code	Exclusivity Expiration
N200533	002	I - 656	Aug 28, 2015
N200533	002	NCE	Nov 20, 2013
N200533	002	NDF	Aug 25, 2014

Additional information:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. These patents may not be flagged with respect to other claims which may apply.

[View a list of all patent use codes](#)

[View a list of all exclusivity codes](#)

[Return to Electronic Orange Book Home Page](#)⁶

FDA/Center for Drug Evaluation and Research

Office of Generic Drugs

Division of Labeling and Program Support

Update Frequency:

Orange Book Data - **Monthly**

Generic Drug Product Information & Patent Information - **Daily**

Orange Book Data Updated Through November 2014

Patent and Generic Drug Product Data Last Updated December 18, 2014

Links on this page:

1. <http://www.addthis.com/bookmark.php?u508=true&v=152&username=fdamain>
2. <http://www.addthis.com/bookmark.php>
3. <http://www.fda.gov/default.htm>
4. <http://www.fda.gov/Drugs/InformationOnDrugs/default.htm>
5. [../default.cfm](#)
6. [../default.cfm](#)

Note: If you need help accessing information in different file formats, see [Instructions for Downloading Viewers and Players](#).

[Accessibility Contact](#) [FDA Careers](#) [FDA Basics](#) [FOIA No Fear Act](#) [Site Map](#) [Transparency](#) [Website Policies](#)



U.S. Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
Ph. 1-888-INFO-FDA (1-888-463-6332)
[Email FDA](#)



[For Government](#) [For Press](#)

[Combination Products](#) [Advisory Committees](#) [Science & Research](#) [Regulatory Information](#) [Safety](#) [Emergency](#) [Preparedness](#) [International Programs](#) [News & Events](#) [Training and Continuing Education](#) [Inspections/Compliance](#) [State & Local Officials](#) [Consumers](#) [Industry](#) [Health Professionals](#) [FDA Archive](#)



Links on this page:



[FDA Home](#)³ [Drug Databases](#)⁴ [Orange Book](#)⁵

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Patent and Exclusivity Search Results from query on Appl No 200533 Product 003 in the OB_Rx list.

Patent Data

Appl No	Prod No	Patent No	Patent Expiration	Drug Substance Claim	Drug Product Claim	Patent Use Code	Delist Requested
N200533	003	6071970	Jun 6, 2017			U - 1178	
N200533	003	6071970	Jun 6, 2017			U - 1276	
N200533	003	7994364	Jun 27, 2025	Y	Y	U - 1178	
N200533	003	7994364	Jun 27, 2025	Y	Y	U - 1276	
N200533	003	8075872	Nov 20, 2023		Y		
N200533	003	8114383	Oct 10, 2024		Y		Y
N200533	003	8309060	Nov 20, 2023		Y	U - 1178	
N200533	003	8309060	Nov 20, 2023		Y	U - 1276	
N200533	003	8420056	Nov 20, 2023		Y		
N200533	003	8536130	Sep 22, 2028			U - 1276	
N200533	003	RE39593	Aug 5, 2022	Y	Y	U - 1178	
N200533	003	RE39593	Aug 5, 2022	Y	Y	U - 1276	

Exclusivity Data

Appl No	Prod No	Exclusivity Code	Exclusivity Expiration
N200533	003	I - 656	Aug 28, 2015
N200533	003	NCE	Nov 20, 2013
N200533	003	NDF	Aug 25, 2014

Additional information:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. These patents may not be flagged with respect to other claims which may apply.

[View a list of all patent use codes](#)

[View a list of all exclusivity codes](#)

[Return to Electronic Orange Book Home Page](#)⁶

FDA/Center for Drug Evaluation and Research

Office of Generic Drugs

Division of Labeling and Program Support

Update Frequency:

Orange Book Data - **Monthly**

Generic Drug Product Information & Patent Information - **Daily**

Orange Book Data Updated Through November 2014

Patent and Generic Drug Product Data Last Updated December 18, 2014

Links on this page:

1. <http://www.addthis.com/bookmark.php?u508=true&v=152&username=fdamain>
2. <http://www.addthis.com/bookmark.php>
3. <http://www.fda.gov/default.htm>
4. <http://www.fda.gov/Drugs/InformationOnDrugs/default.htm>
5. [../default.cfm](#)
6. [../default.cfm](#)

Note: If you need help accessing information in different file formats, see [Instructions for Downloading Viewers and Players](#).

[Accessibility Contact](#) [FDA Careers](#) [FDA Basics](#) [FOIA No Fear Act](#) [Site Map](#) [Transparency](#) [Website Policies](#)



U.S. Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
Ph. 1-888-INFO-FDA (1-888-463-6332)
[Email FDA](#)



[For Government](#) [For Press](#)

[Combination Products](#) [Advisory Committees](#) [Science & Research](#) [Regulatory Information](#) [Safety](#) [Emergency](#) [Preparedness](#) [International Programs](#) [News & Events](#) [Training and Continuing Education](#) [Inspections/Compliance](#) [State & Local Officials](#) [Consumers](#) [Industry](#) [Health Professionals](#) [FDA Archive](#)



Links on this page:



[FDA Home](#)³ [Drug Databases](#)⁴ [Orange Book](#)⁵

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Patent and Exclusivity Search Results from query on Appl No 200533 Product 004 in the OB_Rx list.

Patent Data

Appl No	Prod No	Patent No	Patent Expiration	Drug Substance Claim	Drug Product Claim	Patent Use Code	Delist Requested
N200533	004	6071970	Jun 6, 2017			U - 1178	
N200533	004	6071970	Jun 6, 2017			U - 1276	
N200533	004	7994364	Jun 27, 2025	Y	Y	U - 1178	
N200533	004	7994364	Jun 27, 2025	Y	Y	U - 1276	
N200533	004	8075872	Nov 20, 2023		Y		
N200533	004	8114383	Oct 10, 2024		Y		Y
N200533	004	8309060	Nov 20, 2023		Y	U - 1178	
N200533	004	8309060	Nov 20, 2023		Y	U - 1276	
N200533	004	8420056	Nov 20, 2023		Y		
N200533	004	8536130	Sep 22, 2028			U - 1276	
N200533	004	RE39593	Aug 5, 2022	Y	Y	U - 1178	
N200533	004	RE39593	Aug 5, 2022	Y	Y	U - 1276	

Exclusivity Data

Appl No	Prod No	Exclusivity Code	Exclusivity Expiration
N200533	004	I - 656	Aug 28, 2015
N200533	004	NCE	Nov 20, 2013
N200533	004	NDF	Aug 25, 2014

Additional information:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. These patents may not be flagged with respect to other claims which may apply.

[View a list of all patent use codes](#)

[View a list of all exclusivity codes](#)

[Return to Electronic Orange Book Home Page](#)⁶

FDA/Center for Drug Evaluation and Research

Office of Generic Drugs

Division of Labeling and Program Support

Update Frequency:

Orange Book Data - **Monthly**

Generic Drug Product Information & Patent Information - **Daily**

Orange Book Data Updated Through November 2014

Patent and Generic Drug Product Data Last Updated December 18, 2014

Links on this page:

1. <http://www.addthis.com/bookmark.php?u508=true&v=152&username=fdamain>
2. <http://www.addthis.com/bookmark.php>
3. <http://www.fda.gov/default.htm>
4. <http://www.fda.gov/Drugs/InformationOnDrugs/default.htm>
5. [../default.cfm](#)
6. [../default.cfm](#)

Note: If you need help accessing information in different file formats, see [Instructions for Downloading Viewers and Players](#).

[Accessibility Contact](#) [FDA Careers](#) [FDA Basics](#) [FOIA No Fear Act](#) [Site Map](#) [Transparency](#) [Website Policies](#)



U.S. Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
Ph. 1-888-INFO-FDA (1-888-463-6332)
[Email FDA](#)



[For Government](#) [For Press](#)

[Combination Products](#) [Advisory Committees](#) [Science & Research](#) [Regulatory Information](#) [Safety](#) [Emergency](#) [Preparedness](#) [International Programs](#) [News & Events](#) [Training and Continuing Education](#) [Inspections/Compliance](#) [State & Local Officials](#) [Consumers](#) [Industry](#) [Health Professionals](#) [FDA Archive](#)



Links on this page:



[FDA Home](#)³ [Drug Databases](#)⁴ [Orange Book](#)⁵

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Patent and Exclusivity Search Results from query on Appl No 200533 Product 005 in the OB_Rx list.

Patent Data

Appl No	Prod No	Patent No	Patent Expiration	Drug Substance Claim	Drug Product Claim	Patent Use Code	Delist Requested
N200533	005	6071970	Jun 6, 2017			U - 1178	
N200533	005	6071970	Jun 6, 2017			U - 1276	
N200533	005	7994364	Jun 27, 2025	Y	Y	U - 1178	
N200533	005	7994364	Jun 27, 2025	Y	Y	U - 1276	
N200533	005	8075872	Nov 20, 2023		Y		
N200533	005	8114383	Oct 10, 2024		Y		Y
N200533	005	8309060	Nov 20, 2023		Y	U - 1178	
N200533	005	8309060	Nov 20, 2023		Y	U - 1276	
N200533	005	8420056	Nov 20, 2023		Y		
N200533	005	8536130	Sep 22, 2028			U - 1276	
N200533	005	RE39593	Aug 5, 2022	Y	Y	U - 1178	
N200533	005	RE39593	Aug 5, 2022	Y	Y	U - 1276	

Exclusivity Data

Appl No	Prod No	Exclusivity Code	Exclusivity Expiration
N200533	005	I - 656	Aug 28, 2015
N200533	005	NCE	Nov 20, 2013
N200533	005	NDF	Aug 25, 2014

Additional information:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. These patents may not be flagged with respect to other claims which may apply.

[View a list of all patent use codes](#)

[View a list of all exclusivity codes](#)

[Return to Electronic Orange Book Home Page](#)⁶

FDA/Center for Drug Evaluation and Research

Office of Generic Drugs

Division of Labeling and Program Support

Update Frequency:

Orange Book Data - **Monthly**

Generic Drug Product Information & Patent Information - **Daily**

Orange Book Data Updated Through November 2014

Patent and Generic Drug Product Data Last Updated December 18, 2014

Links on this page:

1. <http://www.addthis.com/bookmark.php?u508=true&v=152&username=fdamain>
2. <http://www.addthis.com/bookmark.php>
3. <http://www.fda.gov/default.htm>
4. <http://www.fda.gov/Drugs/InformationOnDrugs/default.htm>
5. [../default.cfm](#)
6. [../default.cfm](#)

Note: If you need help accessing information in different file formats, see [Instructions for Downloading Viewers and Players](#).

[Accessibility Contact](#) [FDA Careers](#) [FDA Basics](#) [FOIA No Fear Act](#) [Site Map](#) [Transparency](#) [Website Policies](#)



U.S. Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
Ph. 1-888-INFO-FDA (1-888-463-6332)
[Email FDA](#)



[For Government](#) [For Press](#)

[Combination Products](#) [Advisory Committees](#) [Science & Research](#) [Regulatory Information](#) [Safety](#) [Emergency](#) [Preparedness](#) [International Programs](#) [News & Events](#) [Training and Continuing Education](#) [Inspections/Compliance](#) [State & Local Officials](#) [Consumers](#) [Industry](#) [Health Professionals](#) [FDA Archive](#)



Links on this page:

OTC Drug Product List. Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics. Evaluation and Research List. Discontinued Drug Product List. Orphan Products Designations and Approvals List. Approved prescription drug with therapeutic equivalence evaluations. Drug products with Biologics Evaluation and Research. List of approved products that have been discontinued from marketing. 1.2 Therapeutic Equivalence-Related Terms. Drug products are considered therapeutic equivalents if they are all of the following. Pharmaceutical equivalents. Bioequivalent. Description: The publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the List, commonly known as the Orange Book), identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the Act). Home page url. Download or read it online for free here: Download link (19MB, PDF). Similar books. Medicines By Design - National Institutes of Health This book about pharmacology explains how scientists unravel the many different ways medicines work in the body and how this informat

The Drug Price and Competition Act (Hatch-Waxman Act) requires FDA to publish Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. The Orange Book identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act. The publication does not include drugs on the market approved only on the basis of safety (covered by the ongoing Drug Efficacy Study). Get downloadable PDFs of the FDA Orange Book. Annual editions and monthly supplements from 1980 through October 2019. DrugPatentWatch Orange Book PDF Library. Approved Drug Products with Therapeutic Equivalence Evaluations. Orange Book Annual Editions. Order Individual PDFs. Subscribe to the Complete Orange Book Library. FDA Orange Book Annual Editions. 1st Edition (1980) 2nd Edition (1981) 3rd Edition (1982) 4th Edition (1983) 5th Edition (1984) 6th Edition (1985) 7th Edition (1987) 8th Edition (1988) 9th Edition (1989) 10th Edition (1990) 11th Edition (1991) 12th Edition (1992) 13th Edition (1993) 14th Edition (1994) 15th Edition (1995) 16th Edition.